이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MiMedx Group 미래 성장

Future 기준 확인 2/6

MiMedx Group은 연간 수입과 매출이 각각 13.2%와 10.7% 증가할 것으로 예상되고 EPS는 연간 11.6%만큼 증가할 것으로 예상됩니다.

주요 정보

13.2%

수익 성장률

11.6%

EPS 성장률

Biotechs 수익 성장	24.2%
매출 성장률	10.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	01 May 2024

최근 미래 성장 업데이트

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

수익 및 매출 성장 예측

NasdaqCM:MDXG - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	478	73	N/A	N/A	3
12/31/2025	406	56	89	94	6
12/31/2024	361	45	60	64	6
3/31/2024	335	68	34	37	N/A
12/31/2023	321	56	25	27	N/A
9/30/2023	309	11	8	11	N/A
6/30/2023	295	-6	-4	-1	N/A
3/31/2023	281	-18	-15	-12	N/A
12/31/2022	268	-27	-21	-18	N/A
9/30/2022	261	-34	-17	-16	N/A
6/30/2022	256	-28	-12	-10	N/A
3/31/2022	258	-19	-7	-6	N/A
12/31/2021	242	-18	-5	-2	N/A
9/30/2021	260	-35	-14	-9	N/A
6/30/2021	261	-83	-25	-20	N/A
3/31/2021	246	-88	-30	-25	N/A
12/31/2020	248	-83	-35	-30	N/A
9/30/2020	256	-73	-46	-43	N/A
6/30/2020	281	-8	-44	-42	N/A
3/31/2020	294	-17	-39	-36	N/A
12/31/2019	299	-26	-42	-39	N/A
9/30/2019	315	-54	-18	-15	N/A
6/30/2019	314	-67	-14	-8	N/A
3/31/2019	342	-48	3	10	N/A
12/31/2018	359	-30	26	36	N/A
9/30/2018	354	41	46	55	N/A
6/30/2018	352	59	61	70	N/A
3/31/2018	333	65	55	62	N/A
12/31/2017	321	65	N/A	63	N/A
9/30/2017	303	35	N/A	59	N/A
6/30/2017	283	21	N/A	44	N/A
3/31/2017	264	15	N/A	37	N/A
12/31/2016	222	0	N/A	24	N/A
9/30/2016	227	20	N/A	14	N/A
6/30/2016	212	23	N/A	18	N/A
3/31/2016	200	27	N/A	14	N/A
12/31/2015	187	29	N/A	19	N/A
9/30/2015	175	20	N/A	23	N/A
6/30/2015	160	17	N/A	24	N/A
3/31/2015	139	11	N/A	23	N/A
12/31/2014	118	6	N/A	17	N/A
9/30/2014	97	1	N/A	9	N/A
6/30/2014	79	-3	N/A	2	N/A
3/31/2014	67	-3	N/A	0	N/A
12/31/2013	59	-4	N/A	0	N/A
9/30/2013	52	-4	N/A	-2	N/A
6/30/2013	44	-8	N/A	-5	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MDXG 의 연간 예상 수익 증가율( 13.2% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: MDXG 의 연간 수익( 13.2% ) US 시장( 14.9% 보다 느리게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: MDXG 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: MDXG 의 수익(연간 10.7% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: MDXG 의 수익(연간 10.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MDXG 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

MiMedx Group 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

Consensus EPS estimates upgraded to US$0.10 loss

Recent updates

MiMedx Group, Inc. Announces the Appointment of Kim Moller to Chief Commercial Officer

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Insider recently sold US$71k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc. Reaffirms Revenue Guidance for 2022

High number of new directors

MiMedx Group, Inc. Forms Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts